Technical Articles

Soquelitinib (CPI-818) has advanced to global Phase III trials for PTCL and Phase II for AD, while the first ITK PROTAC (BSJ-05-037 from Peking University) and Pfizer's dual-target topical inhibitor PF-07245303 have also been reported. These developments indicate that ITK is gradually transitioning from an "early-stage target" to the "clinical validation phase"—for teams still evaluating project initiation or building screening platforms, now may be an opportune time to make strategic moves.

ITK is a core non-receptor tyrosine kinase in the T cell receptor signaling pathway, playing a regulatory role in T cell subset differentiation by controlling PLCγ1 activation and calcium signal intensity.